Dr. Abid on Sequencing Pirtobrutinib After CAR-T

By Melissa Badamo, Patrick Daly, Bilal Abid, MD - Last Updated: October 4, 2024

Bilal Abid, MD, of the University of Texas Health Science Center at Houston, discusses how to approach sequencing pirtobrutinib after chimeric antigen receptor (CAR) T-cell therapy for the management of hematologic malignancies at the Twelfth Annual Meeting of the Society of Hematologic Oncology.

Advertisement

Advertisement
Advertisement
Advertisement
Editorial Board